An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs CLR 1404 I-131 (Primary) ; Dexamethasone
- Indications B cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Multiple myeloma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Sponsors Cellectar Biosciences
- 17 Jul 2017 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
- 17 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 30 Mar 2017 Status changed from not yet recruiting to recruiting, according to a Cellectar Biosciences media release.